Early oncology portfolio execution roadmap
The challenge
We worked with our client to develop a forward-looking early development program evaluation tool that identifies key inflection points, value drivers and risks for the client’s early oncology portfolio. (US was the geographic scope).
Our solution
- Developed a dynamic excel-based tool for program evaluation with key dimensions, value, risk, and inflection points over time
- Filled in gaps using external benchmarks including key program metrics such as timing, cost and risk
- Developed standalone commercial forecast and valuation for each program (n=17) accounting for opportunity size, competitive dynamics, pricing, cost and PTRS considerations
- Developed current and future portfolio snapshot and outcomes
- Ensured repeatable process for future updates over time
The results
We delivered a commercial analysis of the portfolio with regards to relative potential of the programs along with their key value drivers, milestones, risks and gaps over a 10-year time horizon for key stakeholders.
Jump to a slide with the slide dots.
Patient Finding Through Data Tokenization
Refined HCP targeting in rare disease using integrated data, boosting hit rates from 10% to 50% and delivering 3x ROI in 6 months.
Read moreDigital share of voice and sentiment analysis at key congress
Used GenAI to benchmark digital voice in oncology, boosting engagement & leadership via LinkedIn, DEI & clinical messaging.
Read moreData Strategy Development
Future-proofed data strategy with Putnam: gaps identified, vendors vetted, leading to a first US multi-source tokenized DB.
Read more